T2 vs T3 vs T4: Complete Thyroid Hormone Comparison (2026 Research)

The thyroid hormone system does not consist of a single active molecule. It is a conversion cascade - a family of structurally related iodinated compounds that perform distinct biological functions through distinct mechanisms at distinct timescales. T4 (thyroxine) is produced by the thyroid gland in large quantities and enters the bloodstream as the reservoir hormone. T3 (triiodothyronine) is the receptor-active form, produced primarily by peripheral deiodination of T4 and responsible for the classic genomic thyroid hormone signature. 3,5-T2 (3,5-diiodothyronine) is the downstream metabolite of T3 - two iodines rather than three - and acts directly on mitochondrial machinery rather than through nuclear receptors. Each molecule is not just a weaker or stronger version of the others. They are mechanistically distinct actors in a multi-step signaling cascade.

There is also a fourth player worth naming at the outset: reverse T3 (rT3), the inactive mirror-image metabolite produced when the deiodinase system removes an iodine from the wrong position on T4. rT3 competes with active T3 for nuclear receptor binding but does not activate those receptors. In chronic illness and high-inflammation states, rT3 accumulates and functionally blocks the signaling that active T3 should be delivering. Understanding T2, T3, and T4 in parallel requires awareness of rT3 as the shadow metabolite whose excess disrupts the cascade at the T3 level - before T3 can even reach the T2 conversion step downstream.

The comparison that follows breaks down all three active hormones across structure, mechanism, receptor affinity, half-life, TSH suppression potency, and use cases. It is structured specifically to answer the comparison questions that researchers encounter when designing thyroid hormone protocols: how do these molecules differ, where do they complement each other, and why does the bioenergetic research community increasingly argue that complete metabolic signaling requires all three.

Research framing. This article reviews T2, T3, and T4 from a research-context standpoint. All compounds discussed are sold strictly for laboratory research and not for human consumption. See our /faq#legality page for full terms.

The Three Hormones at a Glance

The table below compares T4, T3, and 3,5-T2 across nine parameters that matter most for researchers evaluating the thyroid hormone family.

Reading the table as a whole, the at-a-glance picture is this: T4 is the reservoir - long-lived, weakly receptor-active, requiring conversion to be useful. T3 is the primary genomic signal - moderate half-life, high nuclear receptor affinity, the molecule responsible for the classical thyroid hormone metabolic signature. T2 is the mitochondrial activator - short-lived, weak nuclear receptor affinity, acting directly on cellular energy machinery rather than through gene transcription. The three hormones are not simply decreasing potency along a single axis. They are distinct biological actors whose mechanisms complement rather than duplicate each other.

T4 (Thyroxine): The Prohormone

T4 is the predominant secretory product of the thyroid gland. Roughly 80-90% of thyroid hormone output from the gland is T4 - a molecule with four iodine atoms (positions 3, 5, 3', and 5') and a serum half-life of approximately 7 days. That long half-life makes T4 the most abundant and most stable form in circulation, serving as the body's working reserve of thyroid hormone substrate.

The critical limitation of T4 is that it is not meaningfully active as secreted. Its affinity for nuclear thyroid hormone receptors (TRalpha and TRbeta) is roughly 10 times lower than T3 - low enough that T4 itself contributes minimally to the genomic thyroid signaling cascade at typical circulating concentrations. T4 is more accurately described as a prohormone: a molecule that must be enzymatically converted before it can perform the primary biological function attributed to thyroid hormones.

That conversion is performed by two type 1 (DIO1) and type 2 (DIO2) deiodinase enzymes, which remove the 5' iodine from T4's outer ring to produce T3. DIO1 is expressed primarily in liver, kidney, and thyroid tissue and handles the bulk of systemic T4-to-T3 conversion. DIO2 is expressed in the brain, pituitary, and muscle, and handles local T3 production in those tissues. Both enzymes are selenoproteins - their activity depends on dietary selenium as a cofactor - which is why selenium deficiency is one of the primary impairments of the T4-to-T3 conversion pathway.

In supplementation, T4 is levothyroxine (L-T4), the most prescribed thyroid hormone worldwide. Its 7-day half-life gives it a very flat serum concentration curve and forgiving dosing pharmacokinetics. Its limitation is that it relies entirely on intact deiodinase function to produce its active metabolite - a reliance that becomes problematic in the inflammatory, selenium-deficient, or DIO-polymorphism states common in chronic illness research subjects.

T3 (Triiodothyronine): The Receptor-Active Hormone

T3 is the primary bioactive thyroid hormone. It carries three iodine atoms (positions 3, 5, and 3') and binds nuclear thyroid hormone receptors - TRalpha and TRbeta - with high affinity, establishing T3 as the reference standard for receptor-mediated thyroid hormone action.

The genomic mechanism through which T3 acts is well-characterized. After entering the cell and nucleus, T3 binds TRalpha or TRbeta, which dimerize with retinoid X receptors (RXRs) and bind thyroid hormone response elements (TREs) in the regulatory regions of target genes. This binding initiates transcription of a broad gene set - including genes governing basal metabolic rate, mitochondrial biogenesis, lipid metabolism, cardiac function, and thermoregulation. The metabolic effects that most researchers associate with thyroid hormones - elevated resting metabolic rate, increased oxygen consumption, improved thermogenesis - are primarily the output of this T3-driven genomic cascade.

The time course of T3's genomic effects is worth noting. Gene transcription, mRNA production, protein synthesis, and protein accumulation to physiologically meaningful concentrations takes hours to days. T3's ~24 hour half-life fits this timescale: dosing adjustments have clinically meaningful effects on serum T3 within 24 hours, but the full expression of metabolic changes from a dose adjustment unfolds over 3-7 days as transcription targets accumulate. Sustained-release T3 (SR-T3) formulations are preferred in many research protocols specifically because the flat serum curve they produce more consistently occupies TRalpha and TRbeta throughout the dosing interval without the sharp peak-and-trough that immediate-release formulations produce.

T3 is also the strongest suppressor of the hypothalamic-pituitary-thyroid (HPT) axis among the three active hormones. It binds TRbeta in the pituitary - the receptor isoform primarily responsible for negative feedback on TSH secretion - with high affinity, which makes TSH suppression one of the primary dose-limiting factors in T3 research protocols.

3,5-T2: The Mitochondrial Hormone

3,5-T2 - formally 3,5-diiodo-L-thyronine - is the downstream metabolite of T3, produced primarily when DIO1 removes the 3'-iodine from T3's outer ring. It carries two iodine atoms at positions 3 and 5 of the inner phenyl ring, a positioning that is decisive for its bioactivity: the isomer with one iodine on each ring (3,3'-T2) has negligible metabolic activity, while 3,5-T2 - both iodines inner-ring - is the biologically active form.

What distinguishes 3,5-T2 from both T3 and T4 is its mechanism of action. Rather than activating nuclear thyroid hormone receptors, 3,5-T2 binds directly to subunit Va of cytochrome c oxidase - Complex IV, the terminal enzyme of the mitochondrial electron transport chain. This is a non-genomic interaction that elevates the rate of aerobic respiration within minutes, without requiring gene transcription, mRNA production, or protein synthesis. The landmark paper establishing this mechanism was published by Goglia, Lanni, and colleagues in FEBS Letters in 1994, demonstrating direct mitochondrial binding in rat liver mitochondria independently of nuclear receptor involvement.

The consequence at the cellular level is a rapid increase in electron transport chain throughput, elevated oxygen consumption, increased proton pumping across the inner mitochondrial membrane, and accelerated fatty acid oxidation to supply the reducing equivalents (NADH and FADH2) that the upregulated Complex IV demands. These effects are measurable by indirect calorimetry in animal models within minutes of T2 administration - a time frame that is not compatible with the genomic transcription route and cannot be produced by T3 regardless of dose. For a complete review of the T2 mechanism, isomer specificity, and TSH safety profile, see the 3,5-T2 complete guide.

T2's short half-life - measured in hours compared to T3's ~24 hours - means its mitochondrial effects are more transient and dose-frequency dependent than T3's genomic effects. It also means T2's contribution to HPT-axis suppression is limited: its affinity for TRbeta (the pituitary feedback receptor) is roughly 10-60× lower than T3's, making its TSH-suppression potency approximately 10× lower than T3 at equivalent doses. This is not a limitation - it is the pharmacological property that makes T2 a viable adjunct to T3 protocols without proportionally amplifying HPT-axis downregulation.

Receptor Binding Profile Compared

Receptor affinity is the key parameter explaining why the three hormones have such different safety profiles and HPT-axis impacts despite being structurally similar iodinated thyronines.

T3's high affinity for both TRalpha and TRbeta is what makes it the reference standard. At physiological concentrations, T3 effectively occupies and activates nuclear thyroid hormone receptors in all T3-sensitive tissues: liver, heart, muscle, brain, pituitary. This broad receptor occupancy is responsible for T3's metabolic potency and also for its cardiovascular and HPT-axis effects at elevated doses.

T4's affinity for the same TRalpha and TRbeta receptors is approximately 10× lower than T3. This means T4 at typical circulating concentrations - even though it is present at much higher serum concentrations than T3 - contributes only modestly to direct nuclear receptor activation. The overwhelming majority of T4's biological effect is delivered through its conversion to T3. When deiodinase function is intact, T4 serves as an effective and long-lived T3 precursor; when deiodinase function is impaired, T4's low direct receptor affinity means the reservoir fills but the active signal fails to materialize.

T2's nuclear receptor affinity is approximately 10-60× lower than T3, depending on the receptor isoform and experimental system. This is not a measurement artifact - it reflects the structural reality that the inner-ring diiodo configuration of 3,5-T2 fits the receptor binding pocket less favorably than the T3 triiodo configuration. At physiological or research-relevant concentrations, T2 contributes minimally to nuclear receptor-mediated thyroid signaling. This is why T2's TSH suppression is weak (TRbeta occupancy is low) and why T2 does not produce the cardiovascular adrenergic effects (tachycardia, palpitations) that characterize high-dose T3 exposure. T2's receptor affinity is low enough to leave the classic genomic thyroid signaling pathway essentially to T3, while T2 pursues its own route at the mitochondria.

Mechanism of Action: Genomic vs Mitochondrial

The contrast between T3's genomic mechanism and T2's mitochondrial mechanism is the central distinction for understanding why these two molecules are complementary rather than redundant.

T3 operates through the genomic pathway: nuclear receptor binding → TRE activation → gene transcription → mRNA → protein synthesis → measurable metabolic effect. The timescale for this pathway is hours to days. A T3 dose taken in the morning begins influencing gene transcription within 1-2 hours of receptor occupancy, but the downstream metabolic effects - the proteins that actually shift metabolic rate, lipid oxidation, thermogenesis - require accumulation over 24-72 hours or more. This is why TSH response to a T3 dose change is measurable within 24 hours (receptor binding is immediate) while body temperature normalization in a WT3 protocol typically takes 7-14 days (the full protein-accumulation cascade takes that long to complete).

T2 operates through the non-genomic mitochondrial pathway: direct binding to cytochrome c oxidase subunit Va → elevated Complex IV activity → increased electron transport chain throughput → elevated cellular respiration and oxygen consumption. The timescale for this pathway is minutes. No gene transcription is required. No protein synthesis is required. The enzyme complex is already present in the mitochondrial inner membrane; T2 binding simply increases its activity rate. Animal model indirect calorimetry studies consistently show measurable metabolic rate elevation within minutes of T2 administration - a result that T3 cannot produce in that timeframe regardless of dose.

The complementarity is therefore not a marketing claim - it is a mechanistic reality. T3 addresses the genomic layer of thyroid signaling: the transcription of metabolic genes, the long-term reprogramming of metabolic enzyme profiles, the sustained shift in basal metabolic rate over days and weeks. T2 addresses the mitochondrial floor: the immediate activation of cellular energy machinery at the Complex IV level, the acute thermogenic and fatty acid oxidation effects that operate in real time. A protocol that supplies only T3 activates the genomic layer fully but has no direct route to the mitochondrial layer if T3-to-T2 conversion is impaired. A protocol that supplies only T2 stimulates the mitochondrial layer acutely without the sustained genomic metabolic reprogramming that T3 delivers.

TSH Suppression: How Each Hormone Affects the HPT Axis

TSH (thyroid-stimulating hormone) suppression is the primary safety variable in thyroid hormone research protocols. TSH suppression measures how strongly the hypothalamic-pituitary-thyroid axis is being downregulated by exogenous thyroid hormone input - it is the feedback metric that indicates whether the HPT axis perceives supraphysiological hormone exposure. Sustained below-range TSH is associated in the long-term clinical literature with elevated cardiovascular risk (particularly atrial fibrillation) and decreased bone mineral density.

T3 is the strongest suppressor of the three. Its high TRbeta affinity means that even moderate T3 doses produce meaningful pituitary TRbeta occupancy, sending a strong "enough thyroid hormone is present" signal that reduces TSH secretion. T3 dose escalation in research protocols is primarily limited by TSH suppression - at some point, further dose increases cannot be supported without driving TSH below the clinical reference range.

T4 suppresses TSH as a function of its conversion to T3. T4 itself has weak direct TRbeta affinity, so it does not directly suppress TSH at the same potency as T3. The suppression T4 produces is primarily mediated by the T3 it generates via DIO1 and DIO2 conversion - particularly DIO2 in the pituitary itself, which locally converts T4 to T3 at the feedback site. T4 TSH suppression is therefore dependent on deiodinase function at the pituitary level and is generally slower to change than T3 suppression because the DIO2-mediated local conversion buffers the signal.

T2 is the weakest suppressor of the three by a substantial margin. In rodent models, 3,5-T2 has approximately 10× lower potency than T3 for TSH suppression at equivalent doses. This reflects its 10-60× lower TRbeta affinity: the pituitary receptor that mediates the negative feedback signal sees T2 as a weak ligand and reduces TSH secretion proportionally less than it would for equivalent T3 input. Consumer-tracking data and research-forum reports suggest that oral T2 doses below approximately 300 mcg/day generally do not produce measurable TSH suppression as a primary endpoint, though formal controlled human trials on this endpoint have not been conducted.

The practical implication for combination protocols is direct: adding T2 to an established T3 protocol enhances the bioenergetic output of the combined regimen without proportionally increasing the HPT-axis load. The mitochondrial activation contributed by T2 supplements the genomic activation of T3 without the additional TSH suppression that would result from simply escalating the T3 dose to achieve comparable total metabolic effect.

Use Cases: When Each Is Used in Research

T4 supplementation (levothyroxine) is the most widely used form in standard clinical hypothyroidism management and in research contexts modeling that approach. Its 7-day half-life produces the most stable serum hormone curve of the three, making it easiest to dose once daily. Its limitation is complete dependence on intact deiodinase function: a research subject with DIO1 or DIO2 impairment - from selenium deficiency, inflammation, cortisol excess, or DIO2 polymorphism - will not adequately convert T4 to T3, and T4 supplementation will fail to restore the active thyroid signal despite normal-appearing T4 serum levels.

T3 supplementation (Cytomel, sustained-release T3, WT3 protocols) bypasses the T4-to-T3 conversion bottleneck entirely by delivering the active hormone directly. Research contexts favoring T3 over T4 include: documented DIO2 polymorphism, T4-treated subjects with persistently low free T3 despite normal TSH, the Wilson's WT3 protocol framework for rT3 clearance, and subjects in high-inflammation states where T4 conversion is reliably impaired. Sustained-release T3 is preferred over immediate-release Cytomel in most research-protocol discussions because its flat serum curve avoids the sharp peak-and-trough pharmacokinetics that produce cardiovascular side effects at higher doses. For the complete SR-T3 rationale, see the sustained-release T3 complete guide. Researchers can use the T3 conversion calculator to model dose equivalents across formulations.

T2 supplementation (3,5-diiodothyronine, typically 100-300 mcg/day in research contexts) is used for two overlapping purposes. The first is direct mitochondrial activation: research subjects whose primary variable of interest is Complex IV activity, cellular respiration rate, or acute thermogenic response. The second - and increasingly prominent - purpose is as an adjunct to T3 protocols in subjects where T3-to-T2 conversion is suspected to be impaired. Rather than relying on exogenous T3 to generate T2 via DIO1, the combined approach supplies both directly.

Combination protocols implement this logic at various stages. T4+T3 combinations (such as NDT or T4+Cytomel regimens) address the T4-to-T3 conversion problem. T3+T2 combinations address both the genomic and mitochondrial layers simultaneously. The Wilson's T3+T2 Combo implements the T3+T2 approach at a 1:1 ratio in sustained-release capsules. The forthcoming analysis of who benefits most from the T3+T2 approach - and how it integrates with the WT3 cyclic protocol - is covered in the Wilson's T3+T2 enhanced protocol guide.

Why the Bioenergetic Framework Increasingly Argues for All Three

The evolution of thyroid hormone research protocols over the past 30 years follows a recognizable pattern. The T4-only paradigm - still dominant in standard endocrinology - treats levothyroxine as the complete thyroid hormone replacement. When T4-only research subjects continue experiencing metabolic underperformance despite normal TSH, the T4+T3 framework offers the next step: the conversion problem is addressed by adding direct T3. This is the framework Wilson's Protocol operates within.

What the bioenergetic research community has begun articulating is that T4+T3 is itself incomplete for a subset of research subjects - those in whom the T3-to-T2 conversion step is also impaired. The argument is mechanistic and is developed in full in the T3-to-T2 conversion problem and deiodinase dysfunction guide. In brief: the same selenium deficiency, inflammatory cytokine load, and DIO1 impairment that creates the original need for T3 supplementation also impairs the downstream conversion of T3 to 3,5-T2. A research subject receiving adequate exogenous T3 may have fully supported nuclear receptor signaling - genomic thyroid hormone effects appear to be restored - yet mitochondrial function remains impaired because T2 production from T3 is insufficient.

The progression therefore looks like this:

T4-only → addresses reservoir supply but not conversion → T4+T3 → addresses conversion to active receptor signal but not downstream T2 production → T3+T2 → addresses both the genomic layer (T3) and the mitochondrial layer (T2) directly, bypassing both the T4→T3 and T3→T2 conversion steps

The bioenergetic argument is that the T3+T2 combination represents the most complete coverage of thyroid hormone signaling currently available in research-grade compounds - not because T2 "adds" to T3, but because T2 and T3 operate through entirely different mechanisms (mitochondrial vs genomic) that are both necessary for complete metabolic function. The plateau pattern that appears in many T3 protocol research subjects - adequate free T3, suppressed TSH, normalized rT3, yet persistent metabolic underperformance - is increasingly interpreted as the T2 signal: the mitochondrial floor is undersupported because T3-to-T2 conversion is impaired in the exact population that needed T3 protocol in the first place. This thesis is examined in depth in the T3-to-T2 conversion problem post, which is the centerpiece of this topic cluster.

Frequently Asked Questions

What's the difference between T2, T3, and T4?

T4 (thyroxine) is the prohormone secreted by the thyroid gland in large quantities - it has four iodine atoms, a ~7 day half-life, and weak direct receptor activity that requires enzymatic conversion to T3 to become useful. T3 (triiodothyronine) is the primary receptor-active hormone - three iodine atoms, ~24 hour half-life, high affinity for nuclear thyroid hormone receptors (TRalpha/TRbeta), and the source of the classical genomic thyroid hormone metabolic signature. 3,5-T2 (diiodothyronine) is the downstream metabolite of T3 - two iodine atoms, a half-life measured in hours, and negligible nuclear receptor affinity - acting instead through direct binding to mitochondrial cytochrome c oxidase to elevate cellular respiration acutely. The three are not simply stronger or weaker versions of the same molecule: they are mechanistically distinct actors operating through different pathways on different timescales.

Which is the most active thyroid hormone?

It depends on which type of activity is being measured. For nuclear receptor-mediated genomic activity - the classical thyroid hormone metabolic signature - T3 is the most active, with the highest affinity for TRalpha and TRbeta and the clearest established relationship to gene transcription, metabolic rate regulation, and HPT-axis feedback. For immediate non-genomic mitochondrial activity - direct cytochrome c oxidase stimulation and acute cellular respiration - 3,5-T2 is not less active than T3, it is differently active, operating through a pathway T3 cannot access directly. T4 is the least directly active of the three for both pathways, functioning primarily as a prohormone reservoir. Researchers should be cautious about single-axis "most active" rankings because they obscure the complementary relationship between T3's genomic pathway and T2's mitochondrial pathway.

Does T2 work the same way T3 does?

No - the mechanisms are fundamentally different. T3 acts primarily through nuclear thyroid hormone receptors (TRalpha and TRbeta), binding in the cell nucleus to activate transcription of thyroid hormone-responsive genes, a process that takes hours to days to produce measurable metabolic effects. T2's affinity for those same nuclear receptors is approximately 10-60× lower than T3, so T2 contributes minimally to genomic thyroid signaling. Instead, T2 acts by binding directly to cytochrome c oxidase (Complex IV) in the mitochondrial inner membrane, elevating aerobic respiration acutely in a process measurable within minutes. The two molecules are complementary rather than interchangeable: T3 governs the genomic layer, T2 governs the mitochondrial layer, and each produces effects the other cannot replicate through its own mechanism.

Can you take T2 with T3?

Yes - and the research community's interest in combining them is based on the mechanistic logic that they address non-overlapping pathways. T3 provides nuclear receptor signaling and the genomic thyroid hormone cascade; T2 provides direct mitochondrial activation at the cytochrome c oxidase level. When T3-to-T2 conversion is impaired - by selenium deficiency, inflammation, or DIO1 dysfunction - supplementing T3 alone restores the genomic layer but not the mitochondrial layer, because converting T3 to T2 requires functional deiodinase activity that the impaired research subject may not have; this is precisely the T3→T2 conversion bottleneck that explains why a subset of T3-protocol subjects plateau despite adequate free T3. The Wilson's T3+T2 Combo implements this combination at a 1:1 T3:T2 ratio. The HPT-axis impact of adding T2 alongside T3 is proportionally small because T2's TSH-suppression potency is approximately 10× lower than T3's.

Why is T4 called a "prohormone"?

Because T4's primary biological role is to serve as a substrate for conversion to the active form T3, rather than to directly exert thyroid hormone effects itself. T4's nuclear receptor affinity (TRalpha/TRbeta) is approximately 10× lower than T3, meaning T4 at physiological concentrations activates thyroid hormone receptors only weakly. The overwhelming majority of T4's biological effect is delivered through DIO1/DIO2-catalyzed removal of the 5' outer-ring iodine, producing T3. The "prohormone" designation reflects this: T4 is the circulating reservoir form that must be activated by enzymatic processing before it can drive the genomic thyroid hormone signature. This is the same logic used for other prohormones in endocrinology - the molecule is biologically inert or weakly active as circulated, and is converted to the active form at the target tissue.

Is T2 safer than T3?

In the specific sense of HPT-axis suppression, T2 has a substantially lower risk profile at equivalent doses. T2's ~10× lower TSH-suppression potency means that doses producing meaningful mitochondrial activation are unlikely to drive TSH out of range in the way that comparable T3 doses would. T2 also does not produce the cardiovascular adrenergic effects (tachycardia, palpitations, tremor) that high-dose T3 produces, because those effects are primarily driven by nuclear receptor-mediated genomic signaling, and T2's nuclear receptor affinity is too low to trigger them at research-relevant doses. However, "safer" should not be misread as "without risk at any dose" - T2 is a biologically active thyroid compound and researchers should apply appropriate monitoring and caution. The half-life difference also matters: T2's shorter half-life means its effects are more transient, but any adverse effects would also resolve more quickly than T3 adverse effects would.

Should I take T4, T3, or T2?

This is a research-design question, not a clinical recommendation - all compounds discussed here are sold for laboratory research only. For researchers, the answer depends on what pathway and timescale is being investigated. T4 research investigates the reservoir-to-active-hormone conversion step and its impairments. T3 research investigates nuclear receptor-mediated genomic thyroid signaling, conversion-impairment bypass, and HPT-axis dynamics. T2 research investigates non-genomic mitochondrial activation, the downstream conversion step from T3, and the complementary bioenergetics of the T2 pathway. Combination research using T3+T2 together - as in the Wilson's T3+T2 Combo - investigates the full genomic plus mitochondrial signaling picture in research subjects where both layers are of interest. Each molecule addresses a different part of the thyroid hormone cascade, and the right choice depends on what question is being asked.

What's the difference between 3,5-T2 and 3,3'-T2?

The two diiodothyronine isomers have iodines in different positions on the thyronine scaffold. 3,5-T2 has both iodines on the inner phenyl ring at positions 3 and 5. 3,3'-T2 has one iodine on the inner ring (position 3) and one on the outer ring (position 3'). This positional difference is decisive for bioactivity: 3,5-T2 is the metabolically active isomer that binds cytochrome c oxidase, elevates mitochondrial respiration, and produces measurable metabolic rate and lipid-oxidation effects in animal models. 3,3'-T2 has been evaluated in the same experimental systems and found to have negligible metabolic activity. 3,3'-T2 is also the primary catabolism product of T3 via DIO1 (the 3'-outer-ring iodine is removed from T3 to produce 3,3'-T2), making it the most abundant diiodothyronine isomer in circulation - but abundance does not equal activity. When researchers and supplement formulators refer to metabolically active "T2," they mean 3,5-T2 specifically, and label claims that say only "T2" without specifying the isomer leave the critical identity question unresolved.

Closing Note

The comparison across T4, T3, and 3,5-T2 arrives at a clear structural conclusion: the thyroid hormone cascade is not a single-molecule system with varying potency levels. It is a multi-step conversion cascade in which each downstream product operates through a distinct mechanism, at a distinct timescale, on a distinct cellular target. T4 fills the reservoir. T3 drives the genomic signal. T2 activates the mitochondrial floor. All three are necessary for complete metabolic signaling - which means impairment at any conversion step produces a specific, mechanistically distinct deficit that cannot be fully corrected by simply adding more of the upstream hormone.

The bioenergetic research community has increasingly shifted from asking "which thyroid hormone should we use" toward asking "which conversion steps are blocked in this research subject, and which hormones need to be supplied directly to bypass those blocks." That framework points toward T3+T2 combination protocols for the subset of research subjects in whom both the T4→T3 and T3→T2 conversion steps are impaired - the exact population that chronic-illness thyroid research tends to work with. The mechanistic case for why the T3 protocol plateau often represents a T2 production failure is made in depth in Post 1 of this cluster, the 3,5-T2 complete guide, and in the centerpiece of this cluster, the T3-to-T2 conversion problem guide.

For researchers ready to investigate the combined T3+T2 approach directly, the Wilson's T3+T2 Combo is the research-grade reference product implementing the 1:1 T3:T2 ratio at documented purity. For the full range of thyroid research compounds, see our catalog.